Acetyl Tetrapeptide-5
Eyeseryl — the anti-puffiness eye peptide. A β-alanine-containing acetyl-tetrapeptide claimed to reduce capillary permeability and inhibit glycation-driven cross-linking; low absolute concentrations (0.01 % active) but convincing before/after in manufacturer studies.
A synthetic tetrapeptide containing a non-proteinogenic β-alanine (Ac-β-Ala-His-Ser-His), developed by Lipotec (now Lubrizol) as Eyeseryl® and awarded the New Technology Award at the 2005 Health & Beauty America Conference. Manufacturer-sponsored in-vivo study in 20 female volunteers using a cream formulated to deliver 0.01 % active peptide (from a 10 % Eyeseryl solution) twice daily to the periocular area reported ≥30 % reduction in puffiness in 70 % of subjects at day 15 and 95 % at day 60. Proposed dual mechanism: reduction of vascular permeability (limiting interstitial fluid accumulation) and inhibition of non-enzymatic glycation of dermal proteins. Cosmetic ingredient; not FDA-approved for any medical use.
Mechanism of action
Proposed dual action on the two principal drivers of visible under-eye puffiness: (1) reduction of microvascular capillary permeability, limiting fluid accumulation in the periocular interstitial compartment — possibly via angiotensin-converting-enzyme (ACE) inhibition, consistent with histidine-rich peptides in that pharmacologic class; (2) inhibition of non-enzymatic glycation of collagen and elastin, which limits cross-link accumulation and preserves skin elasticity around the eye. Manufacturer in-vitro and in-vivo data support both mechanisms at low concentrations (~0.01 %). Independent mechanistic replication is limited; most published efficacy evidence is manufacturer-sponsored.
Primary uses
- Topical cosmetic formulations for periocular puffiness and under-eye bags
- Anti-glycation formulations
Typical dosing
The concentrations in circulation come from the ingredient's supplier, and a seller's figure is not a source on this site; no study in the sources read sets one.
Regulatory status
Cosmetic ingredient; not a drug. INCI name: Acetyl Tetrapeptide-5.
Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
Acetyl tetrapeptide-5 (sold as Eyeseryl) has no human trial on PubMed; one cell study includes it in a peptide mixture. This section records what can be checked: its identity, status, and every search we ran.
Identity, computed
| Sequence | Ac-β-Ala-His-Ser-His (Ac-bAla-His-Ser-His) |
| Formula | C20H28N8O7 |
| Average mass | 492.49 g/mol |
| Monoisotopic mass | 492.2081 Da |
| Isoelectric point | 6.5 (net charge -0.52 at pH 7) |
PubChem record 11620163 lists Eyeseryl as this capped tetrapeptide, formula C20H28N8O7 at 492.5 g/mol, which the calculator reproduces. An earlier version of this entry gave C21H30N8O7 and 506.52, one CH2 too heavy; both were corrected on October 4, 2026.
Regulatory status, read October 5, 2026
Drugs@FDA: 0 records for “acetyl tetrapeptide-5”. EMA medicines list: 0 records for “acetyl tetrapeptide-5”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.
What the maker or sellers claim
Claim, from its supplier: Eyeseryl reduces under-eye puffiness by lowering capillary leakage and inhibiting sugar-driven cross-linking of collagen. Lipotec (now part of Lubrizol) supplies this ingredient to cosmetic brands; its technical data sheet is not a peer-reviewed source, so its figures are not repeated here.
What the one indexed study shows
A 2021 study tested five cosmetic peptides, alone and mixed, on human skin fibroblasts aged prematurely with hydrogen peroxide. For acetyl tetrapeptide-5 the authors measured angiotensin-converting enzyme 1 activity and picked its most effective concentration in culture before combining all five into mixtures (Wu et al., 2021). It is a cell-culture result, not a measurement of puffiness or skin.
What we looked for and did not find
No human or animal study and no registry record. The 2020 review in Frontiers this entry cites lists it among cosmetic peptides without new data. As a cosmetic ingredient it needs no FDA approval in the US; cosmetics are not reviewed for effectiveness before sale.
| Source | Query | Results, October 5, 2026 | What it was |
|---|---|---|---|
| PubMed | acetyl tetrapeptide-5 | 1 | the 2021 fibroblast mixture study |
| PubMed | eyeseryl | 0 | |
| ClinicalTrials.gov | eyeseryl | 0 | |
| Drugs@FDA (openFDA) | acetyl tetrapeptide-5 | 0 | the 2021 fibroblast mixture study |
| EMA medicines list | acetyl tetrapeptide-5 | 0 | the 2021 fibroblast mixture study |
References
- [manufacturer] Lipotec / Lubrizol. "Eyeseryl® (Acetyl Tetrapeptide-5) technical data sheet and clinical study brief."
- [review] Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. "Cosmeceutical peptides in the framework of sustainable wellness economy." Front Chem, 2020;8:572923. PMID: 33195061.
- [review] Ferreira MS, Magalhães MC, Sousa-Lobo JM, Almeida IF. "Trending anti-aging peptides." Cosmetics, 2020;7(4):91.
- [pubmed] Wu Y, et al. "Protective and Anti-Aging Effects of 5 Cosmeceutical Peptide Mixtures on Hydrogen Peroxide-Induced Premature Senescence in Human Skin Fibroblasts." Skin Pharmacol Physiol, 2021;34(4):194-202. PMID: 33849044.
Related peptides
Guides & tools
Explore with tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.